Recent News

• 03.10.2025 - 2025 Leerink Partners Global Healthcare Conference
• 03.10.2025 - Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
• 02.11.2025 - Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 02.04.2025 - Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
• 12.05.2024 - Citi 2024 Global Healthcare Conference
• 12.02.2024 - Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
• 11.21.2024 - Jefferies London Healthcare Conference
• 11.18.2024 - Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
• 11.14.2024 - Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
• 11.08.2024 - OSN New York Retina 2024 Meeting

Recent Filings

• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.18.2024 - 8-K Current report
• 11.18.2024 - EX-99.1 EX-99.1
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.07.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.21.2024 - 4 Statement of changes in beneficial ownership of securities